2:00 PM - 2:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
Centivax’s mission is to accelerate the world’s transition to a post-pathogen humanity.
Infectious disease is humanity’s greatest and most ancient enemy. Every human confronts this enemy within months of birth. It has killed millions in every generation since the beginning of time. It has killed more than every war combined.
Our broad-spectrum influenza vaccine can protect against all forms of human flu. We are applying the same technology to HIV and to the novel coronavirus. Broad spectrum vaccines for dengue, malaria, tuberculosis, herpes, RSV, the common cold and many other pathogens will follow. Centuries of scientists have past the torch to this moment, and we are armed with technologies no previous generation had, to win the forever war against these pathogens.
Universal vaccines enable a new generation of pathogens to be defeated forever, making the world a safer and more thriving place for our children.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Founder & CEO